文献速递临床试验与 GCP基础与转化研究

靶向LRRK2的反义寡核苷酸BIIB094治疗帕金森病:1期随机对照试验

LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.
PubMed 文献 · Nat Med · 2026-03-24

REASON研究为首次人体1期随机试验,评估鞘内注射BIIB094在帕金森病患者中的安全性、耐受性、药代动力学和药效学。A部分40人接受单次10-150mg或安慰剂,B部分42人按LRRK2变异状态分层每4周四次40-120mg或安慰剂。不良事件多为轻至中度且非剂量限制,未报告相关严重不良事件;脑脊液LRRK2和磷酸化Rab10水平分别最多降低59%和50%,与LRRK2变异状态无关。

要点

  • BIIB094鞘内给药安全耐受,不良事件多为轻中度且非剂量限制。
  • 脑脊液LRRK2和磷酸化Rab10水平最多降低59%和50%,与LRRK2变异状态无关。
  • 脑脊液溶酶体蛋白水平同步下降,提示可能影响帕金森病病理生理机制。

核心结论

  • BIIB094在帕金森病患者中安全耐受,并能降低脑脊液LRRK2及其下游磷酸化Rab10水平。

研究设计与样本

  • REASON为首次人体1期随机对照试验,分A、B两部分。
  • A部分40名参与者接受单次BIIB094 10-150mg或安慰剂。
  • B部分42名参与者按LRRK2变异状态分层,每4周接受四次BIIB094 40-120mg或安慰剂。

主要发现

  • A部分64.5%(20/31)参与者报告不良事件,B部分84.8%(28/33)报告不良事件。
  • 不良事件主要为轻至中度且非剂量限制,A、B部分均未报告与BIIB094相关的严重不良事件。
  • 全身BIIB094暴露随剂量增加。
  • 脑脊液LRRK2和磷酸化Rab10水平分别最多降低59%和50%,与LRRK2变异状态无关。
  • 脑脊液溶酶体蛋白水平同步降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

LRRK2 (encoding leucine-rich repeat kinase 2) variants are the most common genetic cause of Parkinson's disease (PD). Lowering LRRK2 levels and/or inhibiting LRRK2 activity may modify PD-associated neuropathology. BIIB094 (ION859), an antisense oligonucleotide, targets LRRK2 mRNA for degradation. REASON was a first-in-human randomized phase 1 study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal BIIB094 in patients with PD. In part A, 40 participants received single doses of BIIB094 10-150 mg or placebo. In part B, 42 participants, stratified by LRRK2 variant status, received four doses of BIIB094 40-120 mg or placebo every 4 weeks. Adverse events were reported by 64.5% (20/31) of participants in part A and by 84.8% (28/33) of participants in part B. The events were mainly mild to moderate and not dose limiting. No serious adverse events related to BIIB094 were reported in either part A or B. Systemic BIIB094 exposure increased with dose. Cerebrospinal fluid (CSF) LRRK2 and phosphorylated Rab10 levels were lowered by up to 59% and up to 50%, respectively, irrespective of LRRK2 variant status. Concomitant reductions in CSF lysosomal protein levels suggested a potential mechanism whereby LRRK2 therapeutics may impact underlying PD pathophysiology. ClinicalTrials.gov identifier, NCT03976349 ; EudraCT number, 2018-002995-42.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Mabrouk OS, Tichler B, Arnold HM, et al. LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial. Nat Med. 2026. PMID: 41876647. doi:10.1038/s41591-026-04262-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。